Medprin Regenerative Medical Technologies (301033.SZ): Absorbable regenerative oxidized cellulose hemostatic particles have entered the clinical trial stage.

Medprin Regenerative Medical Technologies (301033.SZ) announces that the company's research and development project "Absorbable Regenerated Oxidized Cellulose Hemostatic Particles" has officially entered the clinical trial phase recently. In surgical procedures, when conventional methods of hemostasis such as ligation are not feasible or ineffective, this product can be used as an adjunct hemostatic product to control oozing from capillaries, veins, and small arteries.